Summary
Behavioural disinhibition implies the loss of restraint over some form of social behaviour. Such disinhibition can be drug induced and, on rare occasions, lead to extreme acts of aggression or violence. Examples of behavioural disinhibition are often considered paradoxical and rare reactions to drugs, but they may in fact be a more severe behavioural manifestation of a general effect that the drug has on emotions and behaviour. However, the incidence of drug-induced behavioural disinhibition varies considerably and cannot be estimated accurately, as accounts stem mainly from case reports rather than from controlled clinical trials. Adverse effects of drugs are rarely, if ever, the sole focus of clinical studies, although they are now monitored more rigorously in controlled trials.
There are numerous anecdotal case reports in the literature of behavioural disinhibition occurring during administration of benzodiazepines, and recent controlled trials have addressed this issue. The incidence varies with the population studied, but tends to be higher in patients with pre-existing poor impulse control. Alcohol (ethanol) potentiates the disinhibiting effect of benzodiazepines. Aberrant forms of disinhibited behaviour may be accompanied by memory loss.
Disinhibition has also been reported after treatment with tricyclic antidepressants, and reports are now appearing that describe disinhibition in patients who have been treated with selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors. These include incidents of akathisia, suicidal urges, agitation, hyperactivity and mania. They are more prevalent in children and those with learning disabilities.
Disinhibition is rare with antipsychotics and non-benzodiazepine anticonvulsants but some isolated case reports contain descriptions of such reactions with newer compounds.
The most important drug variable in drug-induced behavioural disinhibition is dosage, although mode of administration is also important. Discontinuation of the drug is usually expected to resolve behavioural reactions, but in certain cases drug withdrawal may precipitate a reaction. In order to minimise drug-induced behavioural disinhibition, it is essential to always use the minimum dosage necessary, to increase the dosage gradually and to monitor the effects carefully. Multiple drug use should be avoided whenever possible.
Similar content being viewed by others
References
Room R, Collins G, editors. Alcohol and disinhibition: nature and meaning of the link. NIAAA Research Monograph No. 12, DHSS Publications No. (ADM) 83-1246. Washington DC: Government Printing Office, 1983
Jeavons CM, Taylor SP. The control of alcohol-related aggression: redirecting the inebriate’s attention to socially appropriate conduct. Aggress Behav 1985; 11: 93–101
Kukopulos A, Reginaldi D, Ladomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 156–67
Schou M. Is there a lithium withdrawal syndrome? An examination of the evidence. Br J Psychiatry 1993; 163: 514–8
Gorenstein EE, Newman JP. Disinhibitory psychopathology: a new perspective and a model for research. Psychol Rev 1980; 87: 301–15
Gray JA. Elements of a two-process theory of learning. New York: Academic Press, 1975
Gray JA. The psychology of fear and stress. 2nd ed. New York: Cambridge University Press, 1987
Gray JA. The neuropsychology of anxiety. Br J Psychol 1978; 69: 417–34
Patterson CM, Newman JP. Reflectivity and learning from aversive events: toward a psychological mechanism for the syndromes of disinhibition. Psychol Rev 1993; 100: 716–36
Megargee EI. Undercontrolled and overcontrolled personality types in extreme antisocial aggression. Psychol Monogr 1966; 80(3): 1–29
Tyrer P. The benzodiazepine bonanza. Lancet 1974; I: 709–10
Lader M. Benzodiazepines — the opium of the masses. Neuroscience 1978; 3: 159–65
The sudden withdrawal of triazolam — reasons and consequences. Drug Ther Bull 1991; 29: 89–90
Seivewright NA, Dougal W. Benzodiazepine misuse. Curr Opin Psychiatry 1992; 5: 408–11
Bond A, Seijas D, Dawling S, et al. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821–30
Griffiths RR, McCleod DR, Bigelow GE, et al. Relative abuse liability of diazepam and oxazepam: behavioural and subjective dose effects. Psychopharmacology 1984; 84: 147–54
Hindmarch I, Fairweather DB, Rombaut N. Adverse events after triazolam substitution [letter]. Lancet 1993; 341: 55
Rothschild AJ, Bessette MP, Carter-Campbell J. Triazolam and disinhibition [letter]. Lancet 1993; 341: 186
Adam K, Oswald I. Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiatry 1989; 22: 115–9
Kochansky GE, Salzman C, Shader RI, et al. The differential effects of chlordiazepoxide and oxazepam on hostility in a small group setting. Am J Psychiatry 1975; 132: 861–3
Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. Psychopharmacology 1988; 95: 369–73
Rothschild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psychiatry 1992; 53 Suppl.: 69–79
Regestein QR, Reich P. Agitation observed during treatment with newer hypnotic drugs. J Clin Psychiatry 1985; 46: 280–3
Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988; 49:184–8
Hall RCW, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981; 11 Suppl.: 45–9
Fava M, Borofsky GF. Sexual disinhibition during treatment with a benzodiazepine: a case report. Int J Psychiatry Med 1991; 21: 99–104
Fiset L, Milgrom P, Beirne OR. Disinhibition of behaviors with midazolam: report of a case. J Oral Maxillofac Surg 1992; 50: 645–9
Reiter S, Kutcher SP. Disinhibition and anger outbursts in adolescents treated with clonazepam [letter]. J Clin Psychopharmacol 1991; 11: 268
French AP. Dangerously aggressive behavior as a side effect of alprazolam [letter]. Am J Psychiatry 1989; 146: 276
Terrell HB. Behavioural dyscontrol associated with combined use of alprazolam and ethanol [letter]. Am J Psychiatry 1988; 145:1313
Medawarn C, Rassaby E. Triazolam overdose, alcohol, and manslaughter. Lancet 1991; 339: 1515–6
Garza-Trevino ES, Overall JE, Hollister LE, et al. Disinhibition after lorazepam augmentation of antipsychotic medication [letter]. Am J Psychiatry 1991; 148: 1099–100
Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication [letter]. Am J Psychiatry 1991; 148: 1099
Menkes DB. Triazolam-induced nocturnal bingeing with amnesia. Aust NZ J Psychiatry 1992; 26: 320–1
Joseph AB, Wroblewski BA. Paradoxical akathisia caused by clonazepam, clorazepate and lorazepam in patients with traumatic encephalopathy and seizure disorders: a subtype of benzodiazepine-induced disinhibition. Behav Neural 1993; 6: 221–3
Wolf P. Forced normalization. In: Trimble MR, Bolwig TG, editors. Aspects of epilepsy and psychiatry. Chichester: John Wiley, 1986: 101–15
Trimble MR, Cull CA. Antiepileptic drugs, cognitive function and behavior in children. Cleve Clin J Med 1989; 56 Suppl. Pt 1: 140–9
Rosenbaum JF, Woods SW, Groves JE, et al. Emergence of hostility during alprazolam treatment. Am J Psychiatry 1984; 141: 792–3
Pyke RE, Kraus M. Alprazolam in the treatment of panic attack patients with and without major depression. J Clin Psychiatry 1988; 49: 66–8
Greenblatt DJ, Shader RI, Divoll M, et al. Adverse reactions to triazolam, flurazepam and placebo in controlled clinical trials. J Clin Psychiatry 1984; 45: 192–5
Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142: 98–100
Noyes R, DuPont RL, Pecknold JC. Alprazolam in panic disorder and agoraphobia: results from a multicentre trial. II. Patient acceptance, side effects and safety. Arch Gen Psychiatry 1988; 45: 423–8
Cassano GB, Toni C, Petracca A, et al. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Eur Neuropsychopharmacol 1994; 4: 47–53
O’Sullivan GH, Noshirvani H, Basoglu M, et al. Safety and side-effects of alprazolam: controlled study in agoraphobia with panic disorder. Br J Psychiatry 1994; 165: 79–86
Lapierre YD, Labelle A. Manic-like reaction induced by lorazepam withdrawal. Can J Psychiatry 1987; 32: 697–8
Rigby J, Harvey M, Davies DR. Mania precipitated by benzodiazepine withdrawal. ActaPsychiatr Scand 1989; 79:404–7
Ghaziuddin N, Ghaziuddin M. Mania-like reaction induced by benzodiazepine withdrawal in a patient with mental retardation. Can J Psychiatry 1990; 35: 612–3
Risse SC, Whitters A, Burke J, et al. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry 1990; 51: 206–9
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Zisook S, De Vaul RA. Adverse behavioral effects of benzodiazepines. J Fam Pract 1977; 5: 963–6
Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51 Suppl.: 21–6
Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-related akathisia. J Clin Psychopharmacol 1987; 7: 254–7
Rampling D. Aggression as paradoxical response to tricyclic antidepressants. Am J Psychiatry 1978; 135: 117–8
Edwards G. Antidepressants and murder. Psychiatr Bull 1992; 16: 537–9
Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1988; 144: 1403–11
Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804–8
McElroy SL, Keck PE, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995; 56 Suppl.: 49–55
Fava GA. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995; 64: 57–61
Mirin SM, Schatzberg AF, Creasy DE. Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry 1981; 138: 87–9
Arana GW, Kaplan GB. Trazodone-induced mania following desipramine-induced mania in major depressive disorders [letter]. Am J Psychiatry 1985; 142: 386
Rouillon F, Serrurier D, Miller HD, et al. Prophylactic efficacy of maprotiline on unipolar depressive relapse. J Clin Psychiatry 1991; 52: 423–31
Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–6
Edwards JG. Drug choice in depression: selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 1995; 4: 141–59
Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902
D’Arcy PG. Dystonia and withdrawal symptoms with paroxetine [letter]. Int Pharm J 1993; 7: 140
Committee on Safety of Medicines. Medicines Control Agency. Dystonia and withdrawal symptoms with paroxetine. Curr Probl 1993; 19: 1
Lejoyeux M, Rouillon F, Ades J, et al. Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiology. Acta Psychiatr Scand 1992; 85: 249–56
Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991; 6: 51–8
Ramos RT, Gentil V, Gorenstein C. Clomipramine and initial worsening in panic disorder: beyond the ‘jitteriness syndrome’. J Psychopharmacol 1993; 7: 265–9
Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8: 186–212
Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by 3 patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–3
Wirshing WC, VanPutten T, Rosenberg J, et al. Fluoxetine, akathisia and suicidality: is there a causal connection? Arch Gen Psychiatry 1992; 49: 580–1
Healy D. The fluoxetine and suicide controversy. CNS Drugs 1994; 1: 223–31
Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–10
Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685–92
Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991; 52: 108–11
Detre TP, Jarecki H. Modern psychiatric treatment. Philadelphia: Lippincott, 1971
Fava GA. The concept of recovery in affective disorders. Psychother Psychosom 1996; 65: 2–13
King RA, Riddle MA, Chappell PB, et al. Emergence of self destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30: 179–86
Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment [letter]. N Engl J Med 1991; 324: 420
Creaney W, Murray I, Healy D. Antidepressant-induced suicidal ideation. Hum Psychopharmacol 1991; 6: 329–32
Grounds D, Stocky A, Evans P, et al. Antidepressants and side effects. Aust NZ J Psychiatry 1995; 29: 156–7
Troisi AE, Vicario F, Nuccetelli N, et al. Effects of fluoxetine in aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry 1995; 28: 73–6
Lebegue B. Mania precipitated by fluoxetine [letter]. Am J Psychiatry 1987; 144: 1620
Bryois C, Ferrero F. Mania induced by citalopram. Arch Gen Psychiatry 1994; 51: 664–5
Hon D, Preskorn SH. Mania during fluoxetine treatment for recurrent depression. Am J Psychiatry 1989; 146: 1638–9
Laporta M, Chouinard G, Goldbloom D, et al. Hypomania induced by sertraline, a new serotonin reuptake inhibitor. Am J Psychiatry 1987; 144: 1513–4
Burrai C, Bocchetta A, Del Zompo M. Mania and fluvoxamine. Am J Psychiatry 1991; 148: 1263–4
Turner SM, Jacob RG, Beidel DC, et al. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1985; 5: 207–12
Diaferia G, Mundo E, Bianchi Y. Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description. J Clin Psychopharmacol 1994; 14: 78–9
DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 1996; 57: 55–66
Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993; 3: 1–10
Simeon J, Dinicola V, Phil M, et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsych Biol Psychiatry 1990; 14: 791–5
Jain U, Birmaher B, Garcia M, et al. Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 1992; 2: 259–65
Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991; 1: 193–8
Cook Jr EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739–45
Boulos C, Kutcher S, Gardner D, et al. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 1992; 2: 103–11
Riddle MA, Scahill L, King RA, et al. Double-blind trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062–9
Jerome L. Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry 1991; 30: 850–1
Achamallah NS, Decker DH. Mania induced by fluoxetine in an adolescent patient [letter]. Am J Psychiatry 1991; 148:1404
Jafri AB, Greenberg WM. Fluoxetine side effects [letter]. J Am Acad Child Adolesc Psychiatry 1991; 30: 852
Venkataraman S, Naylor MW, King CA. Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31: 276–81
Rosenberg DR, Johnson K, Sahl R. Evolving mania in an adolescent treatment with low-dose fluoxetine. J Child Adolesc Psychopharmacol 1992; 2: 299–306
Ghaziuddin M. Mania induced by sertraline in a prepubertal child [letter]. Am J Psychiatry 1994; 151: 944
Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269–71
Lebert F, Pasquier F, Goudemand M. Euphoria with buspirone after fluoxetine treatment [letter]. Am J Psychiatry 1993; 150: 167
Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 Suppl.: 37–42
Jeffries JJ, Al-Jeshi A. Nefazodone-induced mania [letter]. Can J Psychiatry 1995; 40: 218
Shammi C. Antidepressant-induced mania. Can J Psychiatry 1995; 40: 635–6
Smith B, Prockop DJ. Central nervous system effects of ingestion of L-tryptophan by normal subjects. N Engl J Med 1962; 267: 1338–41
Egan GP, Hammad GEM. Sexual disinhibition with L-tryptophan [letter]. BMJ 1976; 2: 701
Greenwood MH, Friedel J, Bond AJ, et al. The acute effects of intravenous infusion of L-tryptophan in normal subjects. Clin Pharmacol Ther 1974; 16: 455–64
Rodenburg M, Sheldon L, Owen JA. Sexual disinhibition with L-tryptophan. Can J Psychiatry 1992; 37: 666–7
Livingston M. Risperidone: a novel drug for schizophrenia. Prescriber 1993; 5: 19–25
Dwight MM, Keck Jr PE, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994; 344: 554–5
O’Croinin F, Zibin T, Holt L. Re: hypomania associated with risperidone [letter]. Can J Psychiatry 1995; 40: 51
Koek RJ, Kessler CC. Probable induction of mania by risperidone. J Clin Psychiatry 1996; 57: 174–5
Jones H. Risperidone: a review of its pharmacology and use in the treatment of schizophrenia. J Serotonin Res 1997; 4:17–28
Short C, Cooke L. Hypomania induced by gabapentin. Br J Psychiatry 1995; 166: 679–80
Pakalnis A, Drake Jr ME, John K, et al. Forced normalization: acute psychosis after seizure control in seven patients. Arch Neurol 1987; 44: 289–92
Scull DA, Trimble MR. Mania precipitated by carbamazepine withdrawal [letter]. Br J Psychiatry 1995; 167: 698
Depue RA, Spoont MR. Conceptualizing a serotonin trait: a behavioural dimension of constraint. Ann NY Acad Sci 1986; 487: 47–62
Spoont MR. Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 1992; 112: 330–50
Friedman JH. Punding on levodopa. Biol Psychiatry 1994; 36: 350–1
Lejoyeux M, Ades J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994; 2: 132–43
Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a ‘therapeutic window’? J Clin Psychiatry 1992; 53: 272–7
Norman TR, Leonard BE. Fast-acting antidepressants: can the need be met? CNS Drugs 1994; 2: 120–31
Lieberherr S, Scollo-Lavizzari G, Battegay R. Confusional states following administration of short-acting benzodiazepines. Schweiz Rundsch Med Prax 1991; 80: 673–5
Phelan MC.Beclomethasone mania. Br J Psychiatry 1989; 155: 871–2
Martin W, Unlautzer J, Szuba MR Exacerbation of psychosis associated with inhaled albuterol. J Clin Psychopharmacol 1995; 15: 446–7
Pensabeni-Jasper T, Panush RS. Corticosteroid usage: observations at a community hospital. Am J Med Sci 1996; 311:234–9
Lasher TA, Fleishaker JC, Steenwuk RC, et al. Pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323–7
Berry M. Criminal behavior following drug treatment for psychiatric disorders: medicolegal and ethical issues. CNS Drugs 1994; 2(4): 301–12
Stein G. Physical treatments of the personality disorders. Curr Opin Psychiatry 1994; 7: 129–36
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bond, A.J. Drug- Induced Behavioural Disinhibition. Mol Diag Ther 9, 41–57 (1998). https://doi.org/10.2165/00023210-199809010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199809010-00005